Implantable cardioverter defibrillator utilization in the Commonwealth of Massachusetts: (1997-2008)
Norman S. Kato, M.D., Matthew J. Cioffi, M.S., Sharon-Lise T. Normand, Ph.D. Presented at the ACC.11 Scientific Session & Expo. The Implantable cardioverter defibrillator (ICD) used for primary and secondary prevention of sudden cardiac death is well established. Inclusion and exclusion criteria from randomized clinical trials (RCT) influenced the recommendations published in the ACC/AHA clinical practice guidelines. Limited contemporary data are available describing device use in all-payer populations. We tested the hypothesis that ICDs were implanted according to RCT inclusion and exclusion criteria.
No Mortality Advantage of “On” versus “Off”-hours Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Results from the Massachusetts Data Analysis Center Registry
Cubeddu RJ, Lago RM, Zelevinsky K, Lovett AF, Mendoza I, Crane AM, Witzke CF, Normand S-LT, Pomerantsev E, Palacios IF. Presented at the American Heart Association Scientific Sessions, November 2010. A higher mortality rate has been reported in STEMI admissions during off-hours due to lower availability of primary percutaneous coronary intervention (PCI) and longer door-to-balloon-times (DTB). Our findings, based on large registry data demonstrate that despite longer DTB times, similar rates of in-hospital death, recurrent MI, and periprocedural cardiogenic shock may be expected in STEMI patients admitted during off-hours when primary PCI is performed.